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Abstract
Study Objective: Long- term intake of proton pump inhibitors (PPIs) might increase 
the risk of cardiovascular events. One suggested mechanism is that PPIs inhibit the 
enzyme dimethylarginine dimethylaminohydrolase (DDAH) and thereby block the 
degradation of endothelial asymmetrical dimethylarginine (ADMA). Excess ADMA in 
turn leads to impaired endothelial nitric oxide (NO) generation. So far, this mechanism 
has only been established in human cell cultures. Previous studies that examined this 
pathway in human populations measured circulating ADMA and found no association 
with PPI use and excess plasma ADMA. But in a recent study, plasma ADMA was not 
correlated with intracellular ADMA. We therefore focused on changes in plasma cit-
rulline as an indicator for potential DDAH inhibition.
Design: We analyzed the association between regular daily PPI intake and flow- 
mediated dilation (FMD) of the brachial artery as well as plasma concentrations of 
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1  |  INTRODUC TION
Proton pump inhibitors (PPIs) are widely used to treat disorders 
characterized by excessive gastric acid production. For more than 
10 years, PPIs have also been sold over the counter and are often 
consumed without medical supervision. The safety of long- term in-
take of PPIs has received considerable scientific attention in recent 
years, as large and well- controlled cohort studies linked PPI use to 
an increased risk of myocardial infarction and ischemic stroke.1,2 
The elevated risk of myocardial infarction was associated with PPI 
use but not with the use of histamine H2 receptor antagonists.3 
However, in the absence of clear evidence for causality and without 
a mechanism that links PPI use with higher cardiovascular risk, there 
has been no indication for regulatory authorities to restrict their 
availability.4 One approach to improve the evidence is through test-
ing of plausible biological pathways. Several cohort studies indicated 
that an increased risk of myocardial infarction and ischemic stroke in 
PPI users was independent of aspirin or clopidogrel intake,3,5,6 which 
suggests an underlying mechanism that does not directly involve ei-
ther platelet aggregation or change in drug absorption due to a rise 
in gastric pH.3,5 As a result, potential biochemical mechanisms were 
put forward that could explain the effect of PPI intake on the car-
diovascular system.
In particular, results from biochemical, cellular, ex vivo and in 
vivo mouse studies have led to the hypothesis that PPIs may raise in-
tracellular levels of asymmetric dimethylarginine (ADMA), an endog-
enous inhibitor of nitric oxide (NO) synthesis, which is accompanied 
by lower NO formation, depressed endothelium- mediated vasore-
laxation, and increased circulating ADMA.7 The proposed underlying 
mechanism is a PPI- dependent direct inhibition of the activity of the 
major ADMA- degrading enzyme type- 1 dimethylarginine dimethyl-
aminohydrolase (DDAH- 1),7 and thereby blocking of the degradation 
of endothelial ADMA. Excess ADMA in turn leads to impaired endo-
thelial NO generation.
So far, all efforts to reproduce these findings in human studies 
were without success.8– 10 One possible reason for this is that the 
plasma concentration of ADMA does not reflect the intracellular en-
dothelial ADMA concentration very well.11 ADMA might therefore 
not be the best choice to measure the effect of PPIs on endothelial 
NO synthesis via DDAH- 1 inhibition. A look at the biochemical re-
actions involved in endothelial NO synthesis (Figure 1) shows that a 
potential effect of PPIs via DDAH- 1 inhibition should most notably 
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German Federal Ministry of Education 
and Research (BMBF), [grant numbers 
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citrulline, arginine, ADMA, and symmetric dimethylarginine using inverse probability 
weighting to adjust for confounding and censoring.
Data Source: Data of 1298 participants from two independent cohorts of the 
population- based Study of Health in Pomerania were used.
Patients: Participants of the population- based Study of Health in Pomerania are a 
stratified random sample of the study region.
Intervention: Regular daily intake of PPIs.
Measurements: FMD of the brachial artery and plasma concentrations of citrulline, 
arginine, ADMA, and symmetric dimethylarginine.
Main Results: Eighty- seven participants (57.5% female) were regular daily users of 
PPIs. In the fully adjusted models, associations were identified for FMD and plasma 
citrulline concentrations. PPI users revealed a 0.99% (95% CI: −1.96 to −0.02) lower 
FMD and 3.03 µmol/L (95% CI: −4.96 to −1.10) lower plasma citrulline levels as com-
pared to non- users.
Conclusion: Our data provide evidence that long- term intake of PPIs might inhibit 
human DDAH activity, resulting in impaired endothelial NO production and reduced 
vascular function. In the long run, this might explain an increased risk for cardiovascu-
lar diseases associated with long- term PPI use.
K E Y W O R D S
citrulline, endothelium, flow- mediated dilation, nitric oxide, proton pump inhibitor
F I G U R E  1  The role of proton pump inhibitors in endothelial NO 
synthesis
ADMA DMA + citrulline
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result in a decrease of intracellular L- citrulline,12,13 as it is involved in 
both suppressed reactions (Figure 2).
In the current study, we used data from two independent sam-
ples of the population- based Study of Health in Pomerania (SHIP) to 
assess the association between regular daily PPI intake and metab-
olites of the NO pathway, in particular citrulline, arginine, ADMA, 
and symmetric dimethylarginine (SDMA); in addition, we analyzed 
the association between regular daily PPI intake and flow- mediated 
vasodilation (FMD) of the brachial artery as a measure of endothelial 
function.
2  |  METHODS
2.1  |  Study design and population
SHIP consists of two independent samples, SHIP- 0 and SHIP- 
TREND- 0, of adults from a north- eastern German region.14 For the 
present analyses, we used data from SHIP- Trend- 0 (age range of par-
ticipants at the examination: 20– 79 years) and SHIP- 2 (30– 90 years), 
the third examination cycle of SHIP- 0, because these studies included 
measurements of endothelial function (FMD) as well as metabolites of 
the NO pathway (i.e., citrulline, ADMA, arginine). Data collection took 
place between 2008 and 2012. Users of clopidogrel and participants 
who had suffered a previous myocardial infarction or stroke were ex-
cluded (n = 52) to avoid bias introduced by a potential interaction of 
clopidogrel with the PPI omeprazole or reverse causation. Due to rare 
use of PPIs in younger adults, the analysis was restricted to study par-
ticipants aged ≥38 years. The final sample consisted of 1298 subjects 
(Figure S1). The study complies with the Declaration of Helsinki and 
was approved by the Ethics Committee of the University of Greifswald. 
Written informed consent was provided by all participants.
2.2  |  Measures
2.2.1  |  Endothelial function
Measurements of vascular function were performed by standard-
ized ultrasound examinations as described in detail elsewhere.15 In 
brief, FMD of the brachial artery was assessed. Relative changes are 
expressed as a percentage of absolute FMD to baseline diameter. 
FMD values below the 20th percentile (i.e., FMD = 2.29%) were 
considered decreased.15 Changes are described in relation to a mini-
mally clinical important difference (MCID) of 1% for FMD, based 
upon a meta- analysis indicating that 1% increase in brachial FMD 
decreases the risk of cardiovascular events by 13%.16
2.2.2  |  Metabolites involved in NO synthesis
Serum concentrations of citrulline, arginine, ADMA, and SDMA 
were measured using the AbsoluteIDQ p180 Kit (BIOCRATES; Life 
Sciences AG) at the Institute of Clinical Chemistry and Laboratory 
Medicine of the University Medicine Greifswald. 10 µL aliquots of 
each plasma sample were processed as recommended by the manu-
facturer. The kit has proven superior reproducibility in an interna-
tional ring trial.17 Samples were excluded from the analysis, if they 
deviated by more than three standard deviations from the mean. 
Concentrations of analyzed metabolites are reported in µmol/L.
2.2.3  |  PPI intake
Participants were asked to bring to the interview all medications 
taken in the 7 days preceding the examination. The software 
IDOM was used to scan the unique pharmaceutical central num-
bers (Pharmazentralnummer [PZN]). The treatment group consists 
of participants who reported regular daily PPI intake (Anatomical 
Therapeutic Chemical [ATC] code A02BC).
2.2.4  |  Confounders
We controlled for several confounders, assuming that direct causes 
of the exposure or outcome, excluding possible instrumental vari-
ables, would identify a sufficient set of confounding variables.18 
Accordingly, we adjusted for age, sex, smoking status, alcohol con-
sumption, body mass index (BMI), low- density lipoprotein (LDL), 
systolic blood pressure, glycated hemoglobin (HbA1c), the estimated 
glomerular filtration rate (eGFR), high- sensitivity C- reactive protein 
(hsCRP), antiplatelet therapy (ATC B01AC), intake of statins (ATC 
C10AA), aspirin,19 and use of nonsteroidal anti- inflammatory drugs 
(NSAIDs) (ATC M01A). Use of NSAIDs is a major risk factor for gas-
troduodenal ulceration and bleeding, and therefore for PPI intake. 
Studies on the effect of NSAIDs on endothelial function are ambigu-
ous; some identified NSAIDs as risk factors.20 Moreover, several 
studies reported associations between GFR and endothelial func-
tion, although the causal relation is not clear yet.21
Information on age, sex, smoking status (never, former, or 
current), alcohol consumption habits, medical history (including 
previous myocardial infarction and stroke), and drug intake were 
obtained by computer- assisted personal interviews. BMI, defined 
as body weight divided by height squared [kg/m2], and blood 
pressure were measured at the physical examination.14 Non- 
fasting blood samples were taken to determine serum levels of 
F I G U R E  2  The effect of PPI intake 
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LDL cholesterol, creatinine, and hsCRP. HbA1c was determined by 
high- performance liquid chromatography. The eGFR was calcu-
lated according to Levey et al.22
2.3  |  Statistical analysis
We used inverse probability of treatment (IPT) weighting to ad-
just for confounding.23 Propensity scores were estimated from 
a confounder- adjusted logistic regression and used to calculate 
stabilized weights.24 For reporting the balance in each individual 
covariate between treated and reference populations, the standard-
ized difference in prevalence or means was calculated. IPT- weighted 
linear regression models with robust standard errors were used 
to associate regular daily PPI intake with FMD, citrulline, arginine, 
ADMA, and SDMA. We used IPT- weighted quantile regression with 
bootstrapped standard errors to examine the association between 
PPI use and decreased FMD. We examined additive effect modifica-
tion by adding treatment- covariate product terms to the marginal 
structural model.
TA B L E  1  (a) Characteristics of regular daily users of PPIs in the population before and after inverse probability of treatment weighting. (b) 
Outcome variables before and after inverse probability of treatment weighting
Unweighted population Weighted population
No PPI PPI SMD No PPI PPI SMD
(a)
n 1211 87 1210 86
Age [years] 57.05 (11.65) 62.78 (11.21) 0.501 57.43 (11.70) 58.32 (11.15) 0.078
Female (%) 51.1 57.5 0.129 51.5 47.5 0.079
Smoking (%)
Never 42.0 42.5 0.137 42.0 36.9 0.105
Former 42.0 46.0 42.3 45.3
Current 16.0 11.5 15.8 17.8
Alcohol [g/day] 10.17 (13.78) 10.07 (11.84) 0.008 10.07 (13.68) 11.44 (12.68) 0.104
Body mass index [kg/m2] 27.84 (4.27) 29.07 (3.84) 0.302 27.92 (4.31) 28.11 (3.43) 0.048
Low- density lipoprotein 
[mmol/L]
3.44 (0.91) 3.60 (0.89) 0.182 3.45 (0.92) 3.47 (0.79) 0.024
Systolic blood pressure  
[mm Hg]
131.27 (18.47) 130.64 (16.56) 0.036 131.21 (18.40) 131.62 (17.11) 0.023
Hemoglobin A1C [%] 5.36 (0.66) 5.55 (0.65) 0.287 5.37 (0.66) 5.38 (0.52) 0.011
Glomerular filtration rate  
[ml/min]
87.96 (20.06) 79.26 (18.07) 0.456 87.39 (20.05) 85.46 (15.78) 0.107
High- sensitivity C- reactive 
protein [mg/L]
1.88 (2.87) 2.21 (2.03) 0.134 1.91 (2.97) 2.20 (2.12) 0.116
Antiplatelet drugs (%) 10.2 27.6 0.454 11.4 10.6 0.025
Statins (%) 12.1 26.4 0.368 13.1 12.3 0.023
Aspirin (%) 12.2 28.7 0.418 13.3 12.6 0.021
Nonsteroidal anti- 
inflammatory drugs (%)
8.8 11.5 0.088 9.0 7.9 0.040
Enrollment in SHIP- Trend−0 
(%)
34.1 19.5 0.334 33.2 35.4 0.046
(b)
n 1211 87 1210 86
FMD in [%] 5.65 (3.79) 4.80 (3.36) 0.237 5.62 (3.78) 4.63 (3.31) 0.279
Citrulline [µmol/L] 31.57 (8.81) 29.63 (9.44) 0.213 31.62 (8.84) 28.59 (7.93) 0.361
Arginine [µmol/L] 75.31 (19.28) 72.46 (17.09) 0.156 75.33 (19.27) 72.39 (15.34) 0.169
ADMA [µmol/L] 0.51 (0.16) 0.50 (0.10) 0.074 0.51 (0.16) 0.49 (0.12) 0.089
SDMA [µmol/L] 0.53 (0.25) 0.56 (0.24) 0.145 0.53 (0.25) 0.53 (0.26) 0.023
Note: (a) Continuous variables as [mean (standard deviation)]. (b) All variables as [mean (standard deviation)].
Abbreviations: ADMA, asymmetric dimethylarginine; FMD, flow- mediated dilation;PPI, proton pump inhibitors; SDMA, symmetric dimethylarginine; 
SMD, standardized mean difference.
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In additional analyses, we used inverse probability of censoring 
(IPC) weighting to account for possible differential dropout from 
baseline. Stabilized IPC weights were estimated using logistic re-
gression models and combined with IPT weights.24 These combined 
IPT/IPC weights were used to adjust the models for the association 
of PPI intake and FMD, citrulline, arginine, ADMA, and SDMA lev-
els for confounding and censoring. We assessed the robustness of 
observed associations to unmeasured confounding. Specifically, we 
calculated the E- value,25 which indicates the minimum strength of 
the association that an unmeasured confounder would need to have 
with the exposure and the outcome on the risk ratio scale to fully 
account for the observed exposure- outcome association, above and 
beyond measured confounders. The statistical software R (version 
3.6.2, Foundation for Statistical Computing, Vienna, Austria) was 
used.
3  |  RESULTS
Of the 1298 analyzed subjects (51.5% female), 87 participants 
(57.5% female) were regular daily users of PPIs. The predominant 
PPIs were omeprazole (n = 48, ATC code A02BC01) and pantopra-
zole (n = 31, ATC code A02BC02). Confounders in PPI users and non- 
users, respectively, are presented in Table 1a. Before IPT- weighting, 
participants who reported PPI intake were older, had higher BMI, 
lower eGFR, and were more likely to use other medications. After 
IPT- weighting, the PPI and non- PPI populations were well balanced 
on the confounders. Raw and adjusted outcome variables are pre-
sented in Table 1b.
3.1  |  The association of PPI intake with FMD, 
citrulline, arginine, ADMA, and SDMA
In PPI users, FMD and citrulline were reduced. Adjusted for all 
confounders PPI users had a 0.99% (95% confidence interval [CI]: 
−1.96 to −0.02) lower FMD, which matches our MCID of 1%, and a 
3.03 µmol/L (95% CI: −4.96 to −1.10) lower plasma citrulline level 
compared to non- users (Table 2). This reduction is equivalent to 
0.26 standard deviations for FMD and 0.34 standard deviations 
for citrulline. PPI intake was not associated with changes in plasma 
concentrations of arginine, ADMA, and SDMA. An additional analy-
sis using propensity score matching gave similar estimates (FMD: 
−0.94%; Citrulline: −2.56 µmol/L) and slightly wider confidence in-
tervals (FMD: −2.01 to 0.13%; Citrulline: −5.36 to 0.24 µmol/L). The 
quantile regression model indicated that the relation of PPI use with 
decreased FMD was −1.18% (95% CI: −2.18 to −0.17). The effect of 
PPI intake on FMD and citrulline was not modified by systolic blood 
pressure or smoking status.
Analyses that additionally adjusted for censoring using inverse 
probability weighting were in line with our primary results (Table S1). 
In the IPT- weighted linear model for PPI intake and FMD in order to 
explain the regression coefficient of −0.99%, an unmeasured con-
founder would have to be associated with PPI intake by a risk ratio 
of 1.89- fold, above and beyond the measured confounders. For an 
unmeasured confounder to explain the association between PPI use 
and citrulline, the unobserved confounder would need to be related 
to PPI use with a risk ratio of 1.91.
4  |  DISCUSSION
Our study found that regular daily PPI use was associated with 
lower vascular endothelial function and lower plasma citrulline 
concentrations. FMD in PPI users was on average 0.99% lower 
and plasma citrulline levels were reduced by 3.03 µmol/L com-
pared to non- users. In relation to study population means of 
5.59% for FMD and 31.46 µmol/L for citrulline, these differences 
are quite substantial. Quantile regression for the 0.2 quantile 
showed that the effect on vascular function is even stronger in 
individuals with decreased FMD (FMD below 2.29%), where FMD 
was 1.18% lower among PPI users compared to non- users. In 
comparison, a meta- analysis found that the pooled relative risk of 
cardiovascular events per 1% increase in brachial artery FMD, ad-
justed for confounding factors, was 0.87.16 The E- value of 1.9 for 
both FMD and citrulline implies that in order to explain away the 
observed associations an unmeasured confounder would have to 
be associated with PPI intake by a risk ratio of 1.9- fold, above and 
beyond the measured confounders. The strongest confounder in 
our logistic model for estimating the propensity for PPI intake 
was antiplatelet therapy, which was associated with PPI use with 
an odds ratio of 0.87 (approximately equivalent to an inverted risk 
ratio of 1.15, [i.e., 0.87−1]). We found no effect modification on 
FMD or citrulline by systolic blood pressure or smoking status. In 
line with previous studies, there was no association between PPI 
intake and plasma levels of ADMA.8– 10 We are not aware of any 
studies that assessed the effect of PPI intake on plasma SDMA 
or arginine, and our data showed no relationship between these 
variables.
TA B L E  2  Fully adjusted estimates for the association between 
the regular daily intake of PPIs and FMD, as well as plasma 
concentrations of citrulline, arginine, ADMA, and SDMA
Outcome
Regression 
coefficient 95% CI p
FMD in [%] −0.99 −1.96; −0.02 0.045
Citrulline [µmol/L] −3.03 −4.96; −1.10 0.002
Arginine [µmol/L] −2.94 −6.86; 0.98 0.142
ADMA [µmol/L] −0.01 −0.05; 0.02 0.509
SDMA [µmol/L] 0.01 −0.06; 0.07 0.865
Note: Method: inverse probability of treatment weighted linear 
regression with stabilized weights using all the covariates of Table 1.
Abbreviations: ADMA, asymmetric dimethylarginine; FMD, flow- 
mediated dilation; PPIs, proton pump inhibitors (Anatomical 
Therapeutic Chemical (ATC) code A02BC); SDMA, symmetric 
dimethylarginine.
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In biochemical, cellular, ex vivo, and mouse studies, PPIs were 
found to directly inhibit the enzyme DDAH and thereby elevate the 
intracellular concentration of ADMA.7 High ADMA levels are posing 
an increased cardiovascular risk by inhibiting the endothelial nitric 
oxide synthase (eNOS) resulting in reduced production of NO and 
endothelial dysfunction.26– 28 Unexpectedly, studies that sought to 
replicate these findings in humans by hypothesizing higher plasma 
ADMA levels and reduced endothelial function in PPI users have 
been unsuccessful.9,10 Subsequent research therefore focused on 
the proposition of alternative mechanisms, such as accelerated 
endothelial aging.29,30 One possible explanation is that circulating 
ADMA levels are not strongly correlated with intracellular ADMA, 
which is supposed to be affected by PPI intake.11 NO itself is very 
reactive and complex to measure directly. Perhaps citrulline could 
be a suitable marker for the whole system of involved reactions 
leading to reduced endothelial NO synthesis as it is a product of the 
inhibited degradation of ADMA as well as of the inhibited produc-
tion of NO.7,13 Citrulline is involved in the metabolism of ADMA by 
the enzyme DDAH, leading to citrulline and DMA. In addition, it is a 
product of the NO synthesis, where arginine is degraded by eNOS 
into NO and citrulline. Endothelial citrulline levels are therefore 
twofold decreased by DDAH inhibition and may show the biggest 
response to PPI intake. Vascular function on the other hand might 
predominantly be affected by long- term intake of PPIs, exceeding 
the 4 weeks of treatment, that were covered in a previous study.10 
With that in mind, we used plasma citrulline as an indicator for en-
dothelial DDAH inhibition and assessed the resulting effect of reg-
ular daily PPI intake on flow- mediated brachial artery endothelial 
function.
In this context, our results support the notion that PPI intake 
might increase cardiovascular risk by lowering NO availability in en-
dothelial cells and thus are in line with previous experimental re-
search.7 This is the first stringent evidence for PPI caused DDAH 
inhibition resulting in reduced endothelial function in humans.
Our study has several limitations. First, due to the cross- sectional 
design, regular daily PPI use and markers of endothelial function 
were measured at the same time. Lacking respective measurements 
at treatment initiation, we cannot assure that PPI exposure precedes 
the purported effects in time or exclude the possibility that lower-
ing of FMD and citrulline levels had already occurred. Second, we 
had no information about start and duration of PPI intake and used 
self- reported regular daily intake to identify long- term users of PPI 
in our study. This approach left us with only 87 regular daily users 
of PPI (out of 1298) and might have induced selection bias in the 
form of prevalent user bias.31 In addition, modeling prevalent PPI use 
in the analysis implies that confounders are measured after treat-
ment initiation. If confounders are affected by prior treatment, this 
could bias the direct effect estimates of PPI intake.18 We excluded 
users of clopidogrel, and individuals with prior myocardial infarction 
or stroke, to avoid bias due to a potential interaction of clopidogrel 
with the PPI omeprazole or reverse causation. Although our sensitiv-
ity analysis indicates adjustment for a sufficient set of confounders, 
unmeasured confounding might still have been reduced by adjusting 
for further risk factors (e.g. physical exercise, depression, anxiety, 
fatigue) or choosing histamine H2 receptor antagonists as an active 
comparator. Sadly, this was not possible, as the study population in-
cluded only 1 regular daily user of H2 receptor antagonists.
In summary, we provide evidence that long- term intake of PPIs 
might inhibit human DDAH activity and thereby impair endothelial 
NO production and vascular endothelial function. Chronic disrup-
tion of eNOS may explain an increased risk for cardiovascular events 
among long- term users of PPIs, as found in several studies.1,6 As 
PPIs play an important role in the treatment of gastric acid- related 
disorders, more insight into the consequences of long- term intake 
is desired. Studies that relate new PPI intake with the variation of 
endothelial function and plasma citrulline levels measured over time 
could deliver further evidence for PPI- induced DDAH inhibition in 
humans and explain the potential for increased cardiovascular risk 
in long- term PPI users.
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